BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 29
• 30
• 31

• Drug Development

  Merck & Co. Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Classical Hodgkin Lymphoma At American Society of Hematology Annual Meeting

  December 8, 2014

   · 

  8 min read
• Drug Development

  Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen’s NEUPOGEN®

  December 8, 2014

   · 

  6 min read
• Drug Development

  Amgen And Onyx Pharmaceuticals, Inc. Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma

  December 8, 2014

   · 

  18 min read
• Drug Development

  Sunesis Pharmaceuticals, Inc. Announces Presentation Of Results From Phase 3 VALOR Trial At American Society of Hematology Annual Meeting

  December 8, 2014

   · 

  8 min read
• Policy

  Violations Are Isolated Incidents: AngioDynamics CEO Says

  December 8, 2014

   · 

  1 min read
• Drug Development

  TG Therapeutics, Inc. Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic

  December 8, 2014

   · 

  10 min read
• Deals

  Sigma-Aldrich Corporation Stockholders Approve Acquisition By Merck KGaA

  December 8, 2014

   · 

  4 min read
• Drug Development

  Cornerstone Pharmaceuticals, Inc. Commences Phase I Clinical Trial Of CPI-613 For The Treatment Of B-Cell Non-Hodgkin Lymphoma

  December 8, 2014

   · 

  7 min read
• Business

  AVANIR Pharmaceuticals Cancels Previously Scheduled Earnings Call

  December 8, 2014

   · 

  4 min read
• Drug Development

  Cellerant Therapeutics, Inc. To Present Phase 1 Clinical Data On Evaluation Of CLT-008 In Patients With Acute Myeloid Leukemia At The 2014 American Society of Hematology Annual Meeting

  December 8, 2014

   · 

  2 min read